MTOR and central nervous system cancer: The compound promoted the glioma cell cycle arrest via regulating phosphoinositide 3-kinase/protein kinase B (Akt)/mammalian Target Of Rapamycin (mTOR) signaling pathway and induced anti-migration effect via mitogen-activated protein kinases (MAPK) signaling pathway (Luo et al., 2017).